EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)

Maciej Banach, Peter E Penson, Michel Farnier, Zlatko Fras, Gustavs Latkovskis, Ulrich Laufs, Francesco Paneni, Paolo Parini, Matteo Pirro, Željko Reiner, Michal Vrablik, Carlos Escobar

Progress in Cardiovascular Diseases · 2023-07 · 79 · 2-11

DOI: 10.1016/j.pcad.2023.03.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2023-07. Verfasst von Maciej Banach und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Department of Cardiology and Congenital Diseases …. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Anticholesteremic Agents. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD prevalence have been achieved in recent years by the attenuation of risk factors (particularly hypertension and dyslipidaemias) in primary and secondary prevention. Despite the remarkable success of lipid lowering treatments, and of statins in particular, in reducing the risk of CVD, there is still an unmet clinical need for the attainment of guideline lipid-targets in even 2/3 of patients. Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy. By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i.e., the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE). Bempedoic acid has the potential to contribute to the reduction of CVD risk not only as monotherapy, but even further as part of a lipid-lowering combination therapy with ezetimibe, reducing LDL-C cholesterol up to 40%. This position paper of the International Lipid Expert Panel (ILEP) summarises the recent evidence around the efficacy and safety of bempedoic acid and presents practical recommendations for its use, which complement the 'lower-is-better-for-longer' approach to lipid management, which is applied across international guidelines for the management of CVD risk. Practical evidence-based guidance is provided relating to the use of bempedoic acid in atherosclerotic CVD, familial hypercholesterolaemia, and statin intolerance. Although there are still no sufficient data avilable for the role of bempedoic acid in the primary prevention of CVD, its favourable effects on plasma glucose and inflammatory markers makes this drug a rational choice in the patient-centred care of specific groups of primary prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesAnticholesteremic AgentsHumansCholesterol, LDLRisk FactorsCholesterolHeart Disease Risk FactorsDicarboxylic AcidsFatty Acids

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseBempedoic acidETC1002

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLCholesterolAnticholesteremic Agents8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty Acids

Autor:innen und Institutionen

  • Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHR…
  • Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK; Liverpool Centre for Cardiovascular Science, Liverpool, UK.
  • Physiopathology and Epidemiology Cerebro-Cardiovascular (PEC2), University of Burgundy and Franche Comté, Dijon, France.
  • Department of Vascular Disease, University Medical Center Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Institute of Cardiology and Regenerative Medicine, University of Latvia, Riga, Latvia; Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
  • Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Banach, M., Penson, P. E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., Vrablik, M., & Escobar, C. (2023). Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 79, 2-11. https://doi.org/10.1016/j.pcad.2023.03.001

Vancouver

Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases. 2023;79:2-11. doi:10.1016/j.pcad.2023.03.001

BibTeX
@article{Banach2023,
  author = {Banach, Maciej and Penson, Peter E and Farnier, Michel and Fras, Zlatko and Latkovskis, Gustavs and Laufs, Ulrich and Paneni, Francesco and Parini, Paolo and Pirro, Matteo and Reiner, Željko and Vrablik, Michal and Escobar, Carlos},
  title = {Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)},
  journal = {Progress in Cardiovascular Diseases},
  year = {2023},
  volume = {79},
  pages = {2--11},
  doi = {10.1016/j.pcad.2023.03.001}
}
Kostenlos starten →